BridgeBio Pharma Agrees To Sell Up To $1B Of Convertible Preferred Stock To Sixth Street And KKR's HealthCare Royalty
BridgeBio Pharma, Inc. (NASDAQ: BBIO ) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it has entered into an agreement with funds managed by Sixth Street ("Sixth Street") and funds managed by Health